Serum

PROTECT & VISIBLY CORRECT SIGNS OF UV DAMAGE WITH KIEHL'S NEW BETTER SCREEN UV SERUM

Retrieved on: 
Friday, February 2, 2024
Kiehl, Partnership, Serum, Skin, Gelatin, Peptide, SPF, Safety, UV, Cosmetics

Made with broad spectrum SPF 50+ and Collagen Peptide, Better Screen helps to prevent and visibly correct signs of UV damage.

Key Points: 
  • Made with broad spectrum SPF 50+ and Collagen Peptide, Better Screen helps to prevent and visibly correct signs of UV damage.
  • Better Screen UV Serum helps to protect skin against UV damage and is formulated with peptides to help smooth skin and restore firmer feeling skin with each use."
  • – Dr. Nancy Ilaya PHD, Kiehl's Global Scientific Director
    Wear all day and reapply every two hours to protect and visibly correct signs of sun damage.
  • This breakthrough technology visibly improves skin by*:
    Dermatologist-tested for safety, our unique SPF UV Serum appears invisible on all skin tones.

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Retrieved on: 
Thursday, February 1, 2024
Weight loss, Pharmacokinetics, PD, Human, Aes, SAD, Waist, OXM, Obesity, GLP1R, BMI, IND, Safety, Food, GCGR, Glucagon-like peptide-1 receptor, Șaeș, FDA, Fasting, Weight, Body mass index, Rat, Serum, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.

Key Points: 
  • The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of this year.
  • "Clearance of the IND for DA-1726 allows us to proceed with the Phase 1 program for this novel GLP-1 and glucagon dual receptor, a potential new treatment to address the significant obesity market," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo.
  • Secondary endpoints include the PK of DA-1726, assessed via serum concentrations over time and metabolite profiling at the highest doses of DA-1726.
  • Exploratory endpoints will include the effect of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference and body mass index (BMI), among others.

Immunic to Participate in Investor and Scientific Conferences in February

Retrieved on: 
Thursday, February 1, 2024
Abstract, Multiple sclerosis, MD, Research, Serum, Communication, Cleveland Clinic

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:

Key Points: 
  • NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February:
    February 8: BioCapital Europe 2024.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will attend this conference in Amsterdam and host one-on-one investor meetings.
  • To schedule a meeting, please use the BioCapital conference portal or contact Jessica Breu at: [email protected] .
  • Poster Title: Impact of Vidofludimus Calcium on Serum Neurofilament in Progressive MS: Data from the CALLIPER Interim Analysis
    Presenting Author: Robert J.

Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women

Retrieved on: 
Wednesday, January 31, 2024
Hypertension, Mortality, Parent, Pregnancy, Senior, TIME, Proteinuria, LH, Risk assessment, Disease, Biomarker, Patient, FDA, Physician, United, Thermo Fisher Scientific, Invention, Time (magazine), Risk, Pre-eclampsia, Health, Serum, Blood pressure, Hospital, Dietary supplement

BURLINGTON, N.C., Jan. 31, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch and availability of a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia, a life-threatening blood pressure disorder that occurs during pregnancy and the postpartum period.

Key Points: 
  • The test result, a ratio of these two biomarkers, in conjunction with other laboratory tests and clinical assessments, helps clinicians identify which patients hospitalized for hypertensive disorders of pregnancy may be at risk of progressing to severe features of preeclampsia within the next two weeks of the test.
  • This was validated by the PRAECIS study, which examined more than 1,000 pregnant women across 18 hospitals in the U.S.3
    The blood-based test is intended for use in singleton pregnancies between 23+0 and 34+6/7 weeks gestation.
  • Pregnant women who test positive based on the risk stratification sFlt-1/PlGF ratio ≥ 40, along with other indicators of disease, can receive enhanced surveillance and accelerated care before severe features develop.
  • "Labcorp is proud to partner with Thermo Fisher to offer this new test, which is used in the second and third trimester of pregnancy to assess patients hospitalized for hypertensive disorders and offers providers early and objective information to assist in the management of preeclampsia," said Marcia Eisenberg, Ph.D., Senior Vice President and Chief Scientific Officer at Labcorp.

AWARD WINNING BEAUTY BRAND TARAMAR INSPIRED BY ICELAND'S NATURE SECRETS

Retrieved on: 
Wednesday, January 31, 2024
Calendula, Research, Environment, Safety, Skin, Weather, Natural Resources, Kelp, Icelandic, Serum, Cosmetics

REYKJAVIK, Iceland, Jan. 31, 2024 /PRNewswire/ -- TARAMAR, the Icelandic skincare producer, is making waves as a newcomer in the international beauty market.

Key Points: 
  • REYKJAVIK, Iceland, Jan. 31, 2024 /PRNewswire/ -- TARAMAR, the Icelandic skincare producer, is making waves as a newcomer in the international beauty market.
  • What sets TARAMAR apart is their extensive background in food science research, which has led to groundbreaking discoveries of super-food for the skin.
  • Drawing inspiration from Iceland's abundant natural resources, TARAMAR has discovered a treasure trove of ingredients that offer numerous benefits for our skin.
  • As they continue to make strides in the international market, TARAMAR is poised to become a leading name in science-based skincare.

AWARD WINNING BEAUTY BRAND TARAMAR INSPIRED BY ICELAND'S NATURE SECRETS

Retrieved on: 
Wednesday, January 31, 2024
Calendula, Research, Environment, Safety, Skin, Weather, Natural Resources, Kelp, Icelandic, Serum, Cosmetics

REYKJAVIK, Iceland, Jan. 31, 2024 /PRNewswire/ -- TARAMAR, the Icelandic skincare producer, is making waves as a newcomer in the international beauty market.

Key Points: 
  • REYKJAVIK, Iceland, Jan. 31, 2024 /PRNewswire/ -- TARAMAR, the Icelandic skincare producer, is making waves as a newcomer in the international beauty market.
  • What sets TARAMAR apart is their extensive background in food science research, which has led to groundbreaking discoveries of super-food for the skin.
  • Drawing inspiration from Iceland's abundant natural resources, TARAMAR has discovered a treasure trove of ingredients that offer numerous benefits for our skin.
  • As they continue to make strides in the international market, TARAMAR is poised to become a leading name in science-based skincare.

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Retrieved on: 
Tuesday, January 23, 2024
AATD, Serum, Development, Patient, Centerview Partners, AAT, Quality of life, Weil, Gotshal & Manges, Acquisition, Safety, Lazard, CVR, Inflammation, Research and development, Lung, Pharmacokinetics, Security (finance)

INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing.

Key Points: 
  • INBRX-101 is a human recombinant protein that holds the promise of allowing Alpha-1 Antitrypsin Deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing.
  • AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue.
  • Head of Research and Development, Sanofi
    “The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products.
  • Lazard is acting as exclusive financial advisor to Sanofi and Weil, Gotshal & Manges LLP is acting as its legal counsel.

Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial

Retrieved on: 
Saturday, January 27, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bristol Myers Squibb, Serum, Checkmate, Patient, Research, ASCO, Incidence, Society, Cancer, Immunotherapy, Quality of life, Aes, PFS, Abstract, Disclosure, Confidence interval, BMY, Physician, Pharmaceutical industry

In addition, subcutaneous nivolumab displayed noninferior objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) vs. IV Opdivo.

Key Points: 
  • In addition, subcutaneous nivolumab displayed noninferior objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) vs. IV Opdivo.
  • PFS: Median PFS by BICR with subcutaneous nivolumab was 7.23 months and 5.65 months with IV Opdivo.
  • Among patients treated with subcutaneous nivolumab (n=247), grade 3-4 adverse events (AEs) occurred in 35.2% of patients vs. 40.8% of patients treated with IV Opdivo (n=245).
  • “We are thrilled to present this research for the first time evaluating subcutaneous nivolumab, demonstrating noninferiority compared to intravenous Opdivo and supporting subcutaneous nivolumab as a potential new option to improve healthcare efficiency.

Skincare Brand Purdori Featured in the Giving Suite™ at the 75th Emmy® Awards

Retrieved on: 
Friday, January 19, 2024
Rhea, Serum, Skin, Television, Entertainment

LOS ANGELES, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Purdori, a new luxury skincare brand, was a popular gift at the Backstage Creations Giving Suite™ benefitting the Television Academy Foundation for the 75th Emmy ® Awards.

Key Points: 
  • LOS ANGELES, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Purdori, a new luxury skincare brand, was a popular gift at the Backstage Creations Giving Suite™ benefitting the Television Academy Foundation for the 75th Emmy ® Awards.
  • "We're delighted to toast everyone in television, both in front and behind the cameras who work hard to provide us all with beautiful entertainment," said Amy Tse, Marketing Director for Purdori.
  • The full line of Purdori products—including a serum, cream, lotion, eye cream, toner, and cleanser—was provided to nominees, performers, cast members from nominated shows, and 75th Emmys presenters.
  • We are pleased to have shared our pure gift—a full line of Purdori products—to help them prepare their skin for their next red carpet moment."

Mavian Beauty Aids Skincare Absorption This Season With Their Newest Sonic Cleansing Technology

Retrieved on: 
Thursday, January 18, 2024
Serum, Face, Vibration, Skin, System, Beauty, Exercise, Water, Temperature, Ageing, Massage, FDA, Heat, Cosmetics

WETUMPKA, Ala., Jan. 18, 2024 /PRNewswire-PRWeb/ -- Mavian™ Beauty, launched in the fall of 2023, continues unveiling the latest technologically advanced products to consumers with the introduction of the Profound Sonic Facial Cleansing Brush. Using gentle heat and vibrations, the waterproof massaging device purifies pores, exfoliates the skin and locks in freshness for a relaxed, radiant complexion.

Key Points: 
  • WETUMPKA, Ala., Jan. 18, 2024 /PRNewswire-PRWeb/ -- Mavian™ Beauty , launched in the fall of 2023, continues unveiling the latest technologically advanced products to consumers with the introduction of the Profound Sonic Facial Cleansing Brush .
  • Mavian™ Beauty is a leading beauty brand offering devices and products to create a spa experience in the comfort of home.
  • Its 10,000 vibrations per minute open up pores, lift away dirt and dead skin cells and accelerate skincare absorption.
  • Vu highlighted the following steps to incorporate the Profound Sonic Facial Cleansing Brush into daily routines to keep skin plump and hydrated.